Memorial Sloan Kettering Cancer Center
Link between gut microbiota, clinical outcomes generalizable among allogeneic HSCT recipients
Patterns of microbiota disruption, marked by loss of intestinal diversity and single taxa domination, appeared similar among a cohort of patients undergoing allogeneic hematopoietic stem cell transplantation across various centers and geographic areas, according to findings published in The New England Journal of Medicine.
Expert Panel Document Guides CAR-T Use for Advanced B-Cell Lymphoma
The American Society for Transplantation and Cellular Therapy published an expert panel opinion document on the use of chimeric antigen receptor T-cell therapies for patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
Cytogenetic, molecular factors predict prognosis among patients who relapse after allogeneic HSCT
ORLANDO — Cytogenic and molecular factors can help predict prognosis of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allogeneic hematopoietic stem cell transplantation, according to retrospective study results presented at TCT | Transplantation & Cellular Therapy Meetings.
Off-the-shelf CAR T-cell therapy induces durable remissions in relapsed, refractory B-cell malignancies
Timing, patterns of relapse predict survival after HSCT for multiple myeloma
ORLANDO — Time to relapse appeared prognostic for survival among individuals with multiple myeloma who underwent CD34 positive-selected allogeneic hematopoietic stem cell transplantation, according to study results presented at TCT | Transplantation & Cellular Therapy Meetings.
Adjuvant low-dose ipilimumab extends OS vs. high-dose interferon alfa-2b in metastatic melanoma
Adjuvant ipilimumab dosed at 3 mg/kg significantly improved OS compared with high-dose interferon alfa-2b among patients with metastatic unresectable melanoma, according to results of the phase 3 E1609 trial published in Journal of Clinical Oncology.
Talimogene laherparepvec-pembrolizumab combination appears safe, effective in advanced sarcoma
Talimogene laherparepvec in combination with pembrolizumab demonstrated antitumor activity among patients with advanced sarcoma across a range of histologic subtypes, according to results of a single-arm phase 2 study published in JAMA Oncology.
Pancreatic cancer — a changing outlook if diagnosed early
Tumor DNA sequencing to identify appropriate targeted therapies is revolutionizing treatment of a variety of cancers, and pancreatic cancer — a notoriously deadly disease — is no exception.
FDA panel narrowly supports approval of maintenance olaparib in BRCA-mutated pancreatic cancer
An FDA panel today supported approval of olaparib as maintenance treatment for adults with deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic cancer.